David T Curiel
Overview
Explore the profile of David T Curiel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
392
Citations
9844
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rice-Boucher P, Kashentseva E, Dmitriev I, Guo H, Tremblay J, Shoemaker C, et al.
bioRxiv
. 2025 Feb;
PMID: 39974927
Safe and efficient nucleic acid delivery to targeted cell populations remains a significant unmet need in the fields of cell and gene therapy. Towards this end, we pursued Adenoviral vectors...
2.
Weber W, Andoh T, Kreklywich C, Streblow Z, Denton M, Streblow M, et al.
Vaccines (Basel)
. 2024 Sep;
12(9).
PMID: 39340002
Chikungunya virus (CHIKV) is a pathogenic arthritogenic alphavirus responsible for large-scale human epidemics for which a vaccine was recently approved for use. Mayaro virus (MAYV) is a related emerging alphavirus...
3.
Gagne M, Flynn B, Andrew S, Marquez J, Flebbe D, Mychalowych A, et al.
Nat Immunol
. 2024 Sep;
25(10):1913-1927.
PMID: 39227514
A mucosal route of vaccination could prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication at the site of infection and limit transmission. We compared protection against heterologous XBB.1.16 challenge...
4.
Hamed H, Yacoub A, Park M, Eulitt P, Dash R, Sarkar D, et al.
Mol Ther
. 2024 Aug;
32(12):4524.
PMID: 39214081
No abstract available.
5.
Ying B, Darling T, Desai P, Liang C, Dmitriev I, Soudani N, et al.
Nat Immunol
. 2024 Feb;
25(3):578.
PMID: 38360936
No abstract available.
6.
Ying B, Darling T, Desai P, Liang C, Dmitriev I, Soudani N, et al.
Nat Immunol
. 2024 Feb;
25(3):537-551.
PMID: 38337035
A nasally delivered chimpanzee adenoviral-vectored severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine (ChAd-SARS-CoV-2-S) is currently used in India (iNCOVACC). Here, we update this vaccine by creating ChAd-SARS-CoV-2-BA.5-S, which encodes...
7.
Geng K, Rice-Boucher P, Kashentseva E, Dmitriev I, Lu Z, Goedegebuure S, et al.
Viruses
. 2023 Nov;
15(11).
PMID: 38005953
mRNA vaccines have attracted widespread research attention with clear advantages in terms of molecular flexibility, rapid development, and potential for personalization. However, current mRNA vaccine platforms have not been optimized...
8.
Gagne M, Flynn B, Andrew S, Flebbe D, Mychalowych A, Lamb E, et al.
bioRxiv
. 2023 Nov;
PMID: 37986823
Graphical Abstract:
9.
Singh C, Verma S, Reddy P, Diamond M, Curiel D, Patel C, et al.
NPJ Vaccines
. 2023 Aug;
8(1):125.
PMID: 37596281
One of the most preferable characteristics for a COVID-19 vaccine candidate is the ability to reduce transmission and infection of SARS-CoV-2, in addition to disease prevention. Unlike intramuscular vaccines, intranasal...
10.
Rice-Boucher P, Mendonca S, Alvarez A, Sturtz A, Lorincz R, Dmitriev I, et al.
Mol Ther
. 2023 Jul;
31(9):2600-2611.
PMID: 37452494
B cells are the antibody-producing arm of the adaptive immune system and play a critical role in controlling pathogens. Several groups have now demonstrated the feasibility of using engineered B...